XML 59 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Basis of Presentation and Significant Accounting Policies - Summary of Significant Expense Categories Regularly Reviewed CODM (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Significant Accounting Policies [Line Items]    
Collaboration revenue $ 3,554,061 $ 6,002,206
Research and development expenses:    
Total research and development expenses 11,865,654 5,501,527
General and administrative expenses:    
Employee related costs 2,685,556 2,569,394
Stock-based compensation 1,588,667 545,149
Other general and administrative expenses 4,611,534 4,718,938
Total general and administrative expenses 8,885,757 7,833,481
In-process research and development 25,000 543,186
Depreciation 27,361 27,361
Other income, net (1,648,637) (639,365)
Pre-tax loss (15,601,074) (7,263,984)
Income tax benefit (expense) 720,287 (723,852)
Net loss (14,880,787) (7,987,836)
Preclinical product candidates    
Research and development expenses:    
Total research and development expenses 8,313,290 3,314,311
Sponsored research    
Research and development expenses:    
Total research and development expenses 556,265 256,571
Internal research and development expenses, including stock-based compensation    
Research and development expenses:    
Total research and development expenses $ 2,996,099 $ 1,930,645